{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:29:01Z","timestamp":1792114141092,"version":"4.4.0"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T00:00:00Z","timestamp":1558483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T00:00:00Z","timestamp":1558483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1007\/s12325-019-00992-9","type":"journal-article","created":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T00:27:56Z","timestamp":1558571276000},"page":"1518-1531","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Management of Fibrosing Interstitial Lung Diseases"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7192-9149","authenticated-orcid":false,"given":"Toby M.","family":"Maher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim","family":"Wuyts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,22]]},"reference":[{"issue":"1","key":"992_CR1","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12931-019-1022-1","volume":"20","author":"M Kolb","year":"2019","unstructured":"Kolb M, Va\u0161\u00e1kov\u00e1 M. The natural history of progressive fibrosing interstitial lung diseases. Respir Res. 2019;20(1):57.","journal-title":"Respir Res"},{"key":"992_CR2","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","volume":"198","author":"G Raghu","year":"2018","unstructured":"Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS\/ERS\/JRS\/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198:e44\u201368.","journal-title":"Am J Respir Crit Care Med"},{"key":"992_CR3","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/S2213-2600(14)70101-8","volume":"2","author":"G Raghu","year":"2014","unstructured":"Raghu G, Chen SY, Yeh WS, et al. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65\u00a0years and older: incidence, prevalence, and survival, 2001\u201311. Lancet Respir Med. 2014;2:566\u201372.","journal-title":"Lancet Respir Med"},{"key":"992_CR4","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1007\/s12325-018-0693-1","volume":"35","author":"H Strongman","year":"2018","unstructured":"Strongman H, Kausar I, Maher TM. Incidence, prevalence, and survival of patients with idiopathic pulmonary fibrosis in the UK. Adv Ther. 2018;35:724\u201336.","journal-title":"Adv Ther"},{"key":"992_CR5","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/art.39971","volume":"69","author":"JA Zamora-Legoff","year":"2017","unstructured":"Zamora-Legoff JA, Krause ML, Crowson CS, et al. Progressive decline of lung function in rheumatoid arthritis-associated interstitial lung disease. Arthritis Rheumatol. 2017;69:542\u20139.","journal-title":"Arthritis Rheumatol"},{"key":"992_CR6","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1513\/AnnalsATS.201806-362OC","volume":"15","author":"SA Guler","year":"2018","unstructured":"Guler SA, Winstone TA, Murphy D, et al. Does systemic sclerosis-associated interstitial lung disease burn out? Specific phenotypes of disease progression. Ann Am Thorac Soc. 2018;15:1427\u201333.","journal-title":"Ann Am Thorac Soc"},{"key":"992_CR7","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1002\/art.30513","volume":"63","author":"I Marie","year":"2011","unstructured":"Marie I, Hatron PY, Dominique S, et al. Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients. Arthritis Rheum. 2011;63:3439\u201347.","journal-title":"Arthritis Rheum"},{"key":"992_CR8","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1513\/AnnalsATS.201303-069FR","volume":"10","author":"KC Patterson","year":"2013","unstructured":"Patterson KC, Strek ME. Pulmonary fibrosis in sarcoidosis. Clinical features and outcomes. Ann Am Thorac Soc. 2013;10:362\u201370.","journal-title":"Ann Am Thorac Soc"},{"key":"992_CR9","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1378\/chest.12-2685","volume":"144","author":"ER Fern\u00e1ndez P\u00e9rez","year":"2013","unstructured":"Fern\u00e1ndez P\u00e9rez ER, Swigris JJ, Forss\u00e9n AV, et al. Identifying an inciting antigen is associated with improved survival in patients with chronic hypersensitivity pneumonitis. Chest. 2013;144:1644\u201351.","journal-title":"Chest"},{"key":"992_CR10","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/resp.12674","volume":"21","author":"EA Belloli","year":"2016","unstructured":"Belloli EA, Beckford R, Hadley R, et al. Idiopathic non-specific interstitial pneumonia. Respirology. 2016;21:259\u201368.","journal-title":"Respirology"},{"key":"992_CR11","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1513\/AnnalsATS.201801-067OC","volume":"15","author":"SA Guler","year":"2018","unstructured":"Guler SA, Ellison K, Algamdi M, et al. Heterogeneity in unclassifiable interstitial lung disease. A systematic review and meta-analysis. Ann Am Thorac Soc. 2018;15:854\u201363.","journal-title":"Ann Am Thorac Soc"},{"key":"992_CR12","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1183\/09031936.00073012","volume":"41","author":"WA Wuyts","year":"2013","unstructured":"Wuyts WA, Agostini C, Antoniou KM, et al. The pathogenesis of pulmonary fibrosis: a moving target. Eur Respir J. 2013;41:1207\u201318.","journal-title":"Eur Respir J"},{"key":"992_CR13","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","volume":"183","author":"G Raghu","year":"2011","unstructured":"Raghu G, Collard HR, Egan JJ, et al. An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788\u2013824.","journal-title":"Am J Respir Crit Care Med"},{"key":"992_CR14","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1164\/rccm.201506-1063ST","volume":"192","author":"G Raghu","year":"2015","unstructured":"Raghu G, Rochwerg B, Zhang Y, et al. An official ATS\/ERS\/JRS\/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med. 2015;192:e3\u201319.","journal-title":"Am J Respir Crit Care Med"},{"key":"992_CR15","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1136\/ard.2008.096677","volume":"68","author":"O Kowal-Bielecka","year":"2009","unstructured":"Kowal-Bielecka O, Landew\u00e9 R, Avouac J, et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis. 2009;68:620\u20138.","journal-title":"Ann Rheum Dis"},{"key":"992_CR16","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","volume":"76","author":"O Kowal-Bielecka","year":"2017","unstructured":"Kowal-Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76:1327\u201339.","journal-title":"Ann Rheum Dis"},{"key":"992_CR17","unstructured":"Hoffmann-Vold A, Maher T, Philpot E, et al. Assessment of recent evidence to support treatment recommendations in patients with SSc-ILD. Arthritis Rheumatol. 2018;70(suppl 10). \n                    https:\/\/acrabstracts.org\/abstract\/assessment-of-recent-evidence-to-support-treatment-recommendations-in-patients-with-ssc-ild\/\n                    \n                  . Accessed 18 Sept 2018."},{"key":"992_CR18","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1002\/art.40560","volume":"70","author":"A Fern\u00e1ndez-Codina","year":"2018","unstructured":"Fern\u00e1ndez-Codina A, Walker KM, Pope JE. Treatment algorithms for systemic sclerosis according to experts. Arthritis Rheumatol. 2018;70:1820\u20138.","journal-title":"Arthritis Rheumatol"},{"key":"992_CR19","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1056\/NEJMoa1113354","volume":"366","author":"G Raghu","year":"2012","unstructured":"Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu G, Anstrom KJ, et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012;366:1968\u201377.","journal-title":"N Engl J Med"},{"key":"992_CR20","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1401739","volume":"370","author":"FJ Martinez","year":"2014","unstructured":"Idiopathic Pulmonary Fibrosis Clinical Research Network, Martinez FJ, De Andrade JA, et al. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2093\u2013101.","journal-title":"N Engl J Med"},{"key":"992_CR21","unstructured":"Kreuter M, Olson A, Fischer A, et al. Current treatment of patients with non-IPF progressive fibrosing interstitial lung diseases. In: Poster presented at the American Thoracic Society (ATS) international conference, San Diego, May 2018."},{"key":"992_CR22","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13075-018-1517-z","volume":"20","author":"S Adler","year":"2018","unstructured":"Adler S, Huscher D, Siegert E, et al. Systemic sclerosis associated interstitial lung disease\u2014individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group. Arthritis Res Ther. 2018;20:17.","journal-title":"Arthritis Res Ther"},{"key":"992_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/acr.22783","volume":"68","author":"JA Singh","year":"2016","unstructured":"Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2016;68:1\u201325.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"992_CR24","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.rmed.2009.12.009","volume":"104","author":"AC Schutt","year":"2010","unstructured":"Schutt AC, Bullington WM, Judson MA. Pharmacotherapy for pulmonary sarcoidosis: a Delphi consensus study. Respir Med. 2010;104:717\u201323.","journal-title":"Respir Med"},{"key":"992_CR25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1164\/ajrccm\/145.1.3","volume":"145","author":"JI Kokkarinen","year":"1992","unstructured":"Kokkarinen JI, Tukiainen HO, Terho EO. Effect of corticosteroid treatment on the recovery of pulmonary function in farmer\u2019s lung. Am Rev Respir Dis. 1992;145:3\u20135.","journal-title":"Am Rev Respir Dis"},{"issue":"1","key":"992_CR26","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/jcm8010014","volume":"8","author":"LJ De Sadeleer","year":"2018","unstructured":"De Sadeleer LJ, Hermans F, De Dycker E, et al. Effects of corticosteroid treatment and antigen avoidance in a large hypersensitivity pneumonitis cohort: a single-centre cohort study. J Clin Med. 2018;8(1):14.","journal-title":"J Clin Med."},{"key":"992_CR27","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/s12931-017-0686-7","volume":"18","author":"SH Lee","year":"2017","unstructured":"Lee SH, Park MS, Kim SY, et al. Factors affecting treatment outcome in patients with idiopathic nonspecific interstitial pneumonia: a nationwide cohort study. Respir Res. 2017;18:204.","journal-title":"Respir Res"},{"key":"992_CR28","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1517\/14740338.2016.1140743","volume":"15","author":"M Oray","year":"2016","unstructured":"Oray M, Abu Samra K, Ebrahimiadib N, et al. Long-term side effects of glucocorticoids. Expert Opin Drug Saf. 2016;15:457\u201365.","journal-title":"Expert Opin Drug Saf"},{"key":"992_CR29","doi-asserted-by":"publisher","first-page":"3962","DOI":"10.1002\/art.22204","volume":"54","author":"RK Hoyles","year":"2006","unstructured":"Hoyles RK, Ellis RW, Wellsbury J, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum. 2006;54:3962\u201370.","journal-title":"Arthritis Rheum"},{"key":"992_CR30","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1056\/NEJMoa055120","volume":"354","author":"DP Tashkin","year":"2006","unstructured":"Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354:2655\u201366.","journal-title":"N Engl J Med"},{"key":"992_CR31","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1136\/annrheumdis-2014-eular.2342","volume":"73","author":"C Kelly","year":"2014","unstructured":"Kelly C, Palmer E, Gordon J, et al. Pulsed cyclophosphamide in the treatment of rheumatoid arthritis-related interstitial lung disease (RA-ILD). Ann Rheum Dis. 2014;73:74.","journal-title":"Ann Rheum Dis"},{"key":"992_CR32","doi-asserted-by":"publisher","first-page":"A1544","DOI":"10.1164\/rccm.201702-0299ED","volume":"195","author":"P Saunders","year":"2017","unstructured":"Saunders P, Sharma S, Kokosi M, et al. Intravenous cyclophosphamide as a treatment for severe interstitial lung disease. Am J Respir Crit Care Med. 2017;195:A1544.","journal-title":"Am J Respir Crit Care Med"},{"key":"992_CR33","first-page":"613","volume":"25","author":"C Paone","year":"2007","unstructured":"Paone C, Chiarolanza I, Cuomo G, et al. Twelve-month azathioprine as maintenance therapy in early diffuse systemic sclerosis patients treated for 1-year with low dose cyclophosphamide pulse therapy. Clin Exp Rheumatol. 2007;25:613\u20136.","journal-title":"Clin Exp Rheumatol"},{"key":"992_CR34","first-page":"1064","volume":"35","author":"A B\u00e9rezn\u00e9","year":"2008","unstructured":"B\u00e9rezn\u00e9 A, Ranque B, Valeyre D, et al. Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study. J Rheumatol. 2008;35:1064\u201372.","journal-title":"J Rheumatol"},{"key":"992_CR35","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1183\/09031936.99.14511179","volume":"14","author":"J M\u00fcller-Quernheim","year":"1999","unstructured":"M\u00fcller-Quernheim J, Kienast K, Held M, et al. Treatment of chronic sarcoidosis with an azathioprine\/prednisolone regimen. Eur Respir J. 1999;14:1117\u201322.","journal-title":"Eur Respir J"},{"key":"992_CR36","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1378\/chest.12-1728","volume":"144","author":"ADM Vorselaars","year":"2013","unstructured":"Vorselaars ADM, Wuyts WA, Vorselaars VMM, et al. Methotrexate vs azathioprine in second-line therapy of sarcoidosis. Chest. 2013;144:805\u201312.","journal-title":"Chest"},{"key":"992_CR37","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.chest.2016.10.029","volume":"151","author":"J Morisset","year":"2017","unstructured":"Morisset J, Johannson KA, Vittinghoff E, et al. Use of mycophenolate mofetil or azathioprine for the management of chronic hypersensitivity pneumonitis. Chest. 2017;151:619\u201325.","journal-title":"Chest"},{"key":"992_CR38","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.rmed.2016.11.007","volume":"121","author":"JM Oldham","year":"2016","unstructured":"Oldham JM, Lee C, Valenzi E, et al. Azathioprine response in patients with fibrotic connective tissue disease-associated interstitial lung disease. Respir Med. 2016;121:117\u201322.","journal-title":"Respir Med"},{"key":"992_CR39","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1097\/00005382-200310000-00004","volume":"18","author":"H Arakawa","year":"2003","unstructured":"Arakawa H, Yamasaki M, Kurihara Y, et al. Methotrexate-induced pulmonary injury: serial CT findings. J Thorac Imaging. 2003;18:231\u20136.","journal-title":"J Thorac Imaging"},{"key":"992_CR40","unstructured":"Camus P. The drug-induced respiratory disease website: methotrexate. In: Pneumotox online v2.2. \n                    https:\/\/www.pneumotox.com\/drug\/view\/201\/methotrexate\n                    \n                  . Accessed 18 Sept 2018."},{"key":"992_CR41","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","volume":"4","author":"DP Tashkin","year":"2016","unstructured":"Tashkin DP, Roth MD, Clements PJ, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016;4:708\u201319.","journal-title":"Lancet Respir Med"},{"key":"992_CR42","doi-asserted-by":"crossref","unstructured":"Rahaghi FF, Strek ME, Southern BD, et al. Expert consensus on the screening, treatment, and management of patients with SSc-ILD, and the potential future role of anti-fibrotics in a treatment paradigm for SSc-ILD: a Delphi consensus study. In: Poster to be presented at the American Thoracic Society (ATS) international conference, May 2019, Dallas, USA.","DOI":"10.1164\/ajrccm-conference.2019.199.1_MeetingAbstracts.A7445"},{"key":"992_CR43","doi-asserted-by":"publisher","first-page":"640","DOI":"10.3899\/jrheum.121043","volume":"40","author":"A Fischer","year":"2013","unstructured":"Fischer A, Brown KK, Du Bois RM, et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol. 2013;40:640\u20136.","journal-title":"J Rheumatol"},{"key":"992_CR44","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1093\/rheumatology\/kep093","volume":"49","author":"D Daoussis","year":"2010","unstructured":"Daoussis D, Liossis SN, Tsamandas AC, et al. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford). 2010;49:271\u201380.","journal-title":"Rheumatology (Oxford)"},{"key":"992_CR45","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1183\/09031936.00163911","volume":"40","author":"JG Keir","year":"2012","unstructured":"Keir JG, Maher TM, Hansell DM, et al. Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy. Eur Respir J. 2012;40:641\u20136.","journal-title":"Eur Respir J"},{"key":"992_CR46","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/resp.12214","volume":"19","author":"GJ Keir","year":"2014","unstructured":"Keir GJ, Maher TM, Ming D, et al. Rituximab in severe, treatment-refractory interstitial lung disease. Respirology. 2014;19:353\u20139.","journal-title":"Respirology"},{"key":"992_CR47","first-page":"181","volume":"34","author":"G Lepri","year":"2016","unstructured":"Lepri G, Avouac J, Airo P, et al. Effects of rituximab in connective tissue disorders related interstitial lung disease. Clin Exp Rheumatol. 2016;34:181\u20135.","journal-title":"Clin Exp Rheumatol"},{"key":"992_CR48","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1093\/rheumatology\/kex072","volume":"56","author":"MY Md Yusof","year":"2017","unstructured":"Md Yusof MY, Kabia A, Darby M, et al. Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10\u00a0years\u2019 experience at a single centre. Rheumatology (Oxford). 2017;56:1348\u201357.","journal-title":"Rheumatology (Oxford)"},{"key":"992_CR49","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1093\/rheumatology\/key213","volume":"57","author":"G Sircar","year":"2018","unstructured":"Sircar G, Goswami RP, Sircar D, et al. Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial. Rheumatology (Oxford). 2018;57:2106\u201313.","journal-title":"Rheumatology (Oxford)"},{"key":"992_CR50","doi-asserted-by":"publisher","first-page":"841","DOI":"10.3899\/jrheum.170541","volume":"45","author":"TJ Doyle","year":"2018","unstructured":"Doyle TJ, Dhillon N, Madan R, et al. Rituximab in the treatment of interstitial lung disease associated with antisynthetase syndrome: a multicenter retrospective case review. J Rheumatol. 2018;45:841\u201350.","journal-title":"J Rheumatol"},{"key":"992_CR51","unstructured":"Narvaez FJ, Robles Perez A, Luburich P, et al. Efficacy and safety in the middle-long period of rituximab in the treatment of diffuse interstitial pulmonary disease associated with rheumatoid arthritis. Arthritis Rheumatol. 2018;70(suppl 10). \n                    https:\/\/acrabstracts.org\/abstract\/efficacy-and-safety-in-the-middle-long-period-of-rituximab-in-the-treatment-of-diffuse-interstitial-pulmonary-disease-associated-with-rheumatoid-arthritis\/\n                    \n                  . Accessed 18 Sept 2018."},{"key":"992_CR52","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","volume":"387","author":"D Khanna","year":"2016","unstructured":"Khanna D, Denton CP, Jahreis A, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet. 2016;387:2630\u201340.","journal-title":"Lancet"},{"key":"992_CR53","unstructured":"Khanna D, Lin CJF, Kuwana M, et al. Efficacy and safety of tocilizumab for the treatment of systemic sclerosis: results from a phase 3 randomized controlled trial. In: Oral presentation at the American College of Rheumatology (ACR)\/Association of Rheumatology Professionals (ARHP) annual meeting 2018, Chicago, USA."},{"key":"992_CR54","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1001\/jama.2014.6368","volume":"311","author":"JM Van Laar","year":"2014","unstructured":"Van Laar JM, Farge D, Sont JK, et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis. A randomized trial. JAMA. 2014;311:2490\u20138.","journal-title":"JAMA"},{"key":"992_CR55","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/NEJMoa1703327","volume":"378","author":"KM Sullivan","year":"2018","unstructured":"Sullivan KM, Goldmuntz EA, Keyes-Elstein L, et al. Myeloablative autologous stem-cell transplantation for severe scleroderma. N Engl J Med. 2018;378:35\u201347.","journal-title":"N Engl J Med"},{"key":"992_CR56","doi-asserted-by":"crossref","unstructured":"Sullivan KM, Majhail NS, Bredeson C, et al. Systemic sclerosis as an indication for autologous hematopoietic cell transplantation: position statement from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2018;24(10):1961\u20134.","DOI":"10.1016\/j.bbmt.2018.06.025"},{"key":"992_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.healun.2014.06.014","volume":"34","author":"D Weill","year":"2015","unstructured":"Weill D, Benden C, Corris PA, et al. A consensus document for the selection of lung transplant candidates: 2014\u2014an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2015;34:1\u201315.","journal-title":"J Heart Lung Transplant"},{"key":"992_CR58","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1513\/AnnalsATS.201503-177OC","volume":"13","author":"MM Crespo","year":"2016","unstructured":"Crespo MM, Bermudez CA, Dew MA, et al. Lung transplant in patients with scleroderma compared with pulmonary fibrosis. Short- and long-term outcomes. Ann Am Thorac Soc. 2016;13:84\u201392.","journal-title":"Ann Am Thorac Soc"},{"key":"992_CR59","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.healun.2018.03.003","volume":"37","author":"P Prad\u00e8re","year":"2018","unstructured":"Prad\u00e8re P, Tudorache I, Magnusson J, et al. Lung transplantation for scleroderma lung disease: an international, multicenter, observational cohort study. J Heart Lung Transplant. 2018;37:903\u201311.","journal-title":"J Heart Lung Transplant"},{"key":"992_CR60","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.healun.2014.01.858","volume":"33","author":"A Yazdani","year":"2014","unstructured":"Yazdani A, Singer LG, Strand V, et al. Survival and quality of life in rheumatoid arthritis-associated interstitial lung disease after lung transplantation. J Heart Lung Transplant. 2014;33:514\u201320.","journal-title":"J Heart Lung Transplant"},{"key":"992_CR61","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1016\/j.transproceed.2014.09.163","volume":"46","author":"H Ameye","year":"2014","unstructured":"Ameye H, Ruttens D, Benveniste O, et al. Is lung transplantation a valuable therapeutic option for patients with pulmonary polymyositis? Experiences from the Leuven transplant cohort. Transplant Proc. 2014;46:3147\u201353.","journal-title":"Transplant Proc"},{"key":"992_CR62","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.21037\/jtd.2018.02.50","volume":"10","author":"JE Park","year":"2018","unstructured":"Park JE, Kim SY, Song JH, et al. Comparison of short-term outcomes for connective tissue disease-related interstitial lung disease and idiopathic pulmonary fibrosis after lung transplantation. J Thorac Dis. 2018;10:1538\u201347.","journal-title":"J Thorac Dis"},{"key":"992_CR63","doi-asserted-by":"crossref","unstructured":"Wells AU, Brown KK, Flaherty KR, et al. What\u2019s in a name? That which we call IPF, by any other name would act the same. Eur Respir J. 2018;51(5):1800692.","DOI":"10.1183\/13993003.00692-2018"},{"key":"992_CR64","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/ar4230","volume":"15","author":"AJ Gilbane","year":"2013","unstructured":"Gilbane AJ, Denton CP, Holmes AM. Scleroderma pathogenesis: a pivotal role for fibroblasts as effector cells. Arthritis Res Ther. 2013;15:215.","journal-title":"Arthritis Res Ther"},{"key":"992_CR65","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1002\/art.38702","volume":"66","author":"EL Herzog","year":"2014","unstructured":"Herzog EL, Mathur A, Tager AM, et al. Review: interstitial lung disease associated with systemic sclerosis and idiopathic pulmonary fibrosis: how similar and distinct? Arthritis Rheumatol. 2014;66:1967\u201378.","journal-title":"Arthritis Rheumatol"},{"key":"992_CR66","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/S2213-2600(18)30007-9","volume":"6","author":"PJ Wolters","year":"2018","unstructured":"Wolters PJ, Blackwell TS, Eickelberg O, et al. Time for a change: is idiopathic pulmonary fibrosis still idiopathic and only fibrotic? Lancet Respir Med. 2018;6:154\u201360.","journal-title":"Lancet Respir Med"},{"key":"992_CR67","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1378\/chest.09-0510","volume":"136","author":"RM Strieter","year":"2009","unstructured":"Strieter RM, Mehrad B. New mechanisms of pulmonary fibrosis. Chest. 2009;136:1364\u201370.","journal-title":"Chest"},{"key":"992_CR68","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1183\/09059180.00003214","volume":"24","author":"G Bagnato","year":"2015","unstructured":"Bagnato G, Harari S. Cellular interactions in the pathogenesis of interstitial lung diseases. Eur Respir Rev. 2015;24:102\u201314.","journal-title":"Eur Respir Rev"},{"key":"992_CR69","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","volume":"370","author":"TE King Jr","year":"2014","unstructured":"King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2083\u201392.","journal-title":"N Engl J Med"},{"key":"992_CR70","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.3899\/jrheum.151322","volume":"43","author":"D Khanna","year":"2016","unstructured":"Khanna D, Albera C, Fischer A, et al. An open-label, phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: the LOTUSS trial. J Rheumatol. 2016;43:1672\u20139.","journal-title":"J Rheumatol"},{"key":"992_CR71","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","volume":"370","author":"L Richeldi","year":"2014","unstructured":"Richeldi L, Du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2071\u201382.","journal-title":"N Engl J Med"},{"key":"992_CR72","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.rmed.2016.02.001","volume":"113","author":"L Richeldi","year":"2016","unstructured":"Richeldi L, Cottin V, Du Bois RM, et al. Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS\u00ae trials. Respir Med. 2016;113:74\u20139.","journal-title":"Respir Med"},{"key":"992_CR73","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1183\/09031936.00174914","volume":"45","author":"L Wollin","year":"2015","unstructured":"Wollin L, Wex E, Pautsch A, et al. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J. 2015;45:1434\u201345.","journal-title":"Eur Respir J"},{"key":"992_CR74","first-page":"PA903","volume":"50","author":"L Wollin","year":"2017","unstructured":"Wollin L, Ostermann A, Williams C. Nintedanib inhibits pro-fibrotic mediators from T cells with relevance to connective tissue disease-associated interstitial lung disease. Eur Respir J. 2017;50:PA903.","journal-title":"Eur Respir J"},{"key":"992_CR75","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1136\/annrheumdis-2014-207109","volume":"75","author":"J Huang","year":"2016","unstructured":"Huang J, Beyer C, Palumbo-Zerr K, et al. Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis. Ann Rheum Dis. 2016;75:883\u201390.","journal-title":"Ann Rheum Dis"},{"key":"992_CR76","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1136\/annrheumdis-2016-210823","volume":"76","author":"J Huang","year":"2017","unstructured":"Huang J, Maier C, Zhang Y, et al. Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis. Ann Rheum Dis. 2017;76:1941\u20138.","journal-title":"Ann Rheum Dis"},{"key":"992_CR77","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1080\/01902148.2017.1339141","volume":"43","author":"HY Lee","year":"2017","unstructured":"Lee HY, Hur J, Kim IK, et al. Effect of nintedanib on airway inflammation and remodeling in a murine chronic asthma model. Exp Lung Res. 2017;43:187\u201396.","journal-title":"Exp Lung Res"},{"key":"992_CR78","doi-asserted-by":"publisher","first-page":"L998","DOI":"10.1152\/ajplung.00304.2017","volume":"314","author":"EF Redente","year":"2018","unstructured":"Redente EF, Aguilar MA, Black BP, et al. Nintedanib reduces pulmonary fibrosis in a model of rheumatoid arthritis-associated interstitial lung disease. Am J Physiol Lung Cell Mol Physiol. 2018;314:L998\u20131009.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"992_CR79","doi-asserted-by":"publisher","DOI":"10.1177\/2397198319841842","author":"L Wollin","year":"2019","unstructured":"Wollin L, Distler JHW, Denton CP, et al. Rationale for the evaluation of nintedanib as a treatment for systemic sclerosis-associated interstitial lung disease. J Scleroderma Relat Dis. 2019. \n                    https:\/\/doi.org\/10.1177\/2397198319841842\n                    \n                  .","journal-title":"J Scleroderma Relat Dis"},{"key":"992_CR80","doi-asserted-by":"crossref","unstructured":"Walsh SLF. Multidisciplinary evaluation of interstitial lung diseases: current insights: number 1 in the series \u201cRadiology\u201d edited by Nicola Sverzellati and Sujal Desai. Eur Respir Rev. 2017;26(144):170002.","DOI":"10.1183\/16000617.0002-2017"},{"key":"992_CR81","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/S2213-2600(17)30383-1","volume":"5","author":"M Kreuter","year":"2017","unstructured":"Kreuter M, Bendstrup E, Russell AM, et al. Palliative care in interstitial lung disease: living well. Lancet Respir Med. 2017;5:968\u201380.","journal-title":"Lancet Respir Med"},{"key":"992_CR82","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1136\/thoraxjnl-2016-208638","volume":"72","author":"LM Dowman","year":"2017","unstructured":"Dowman LM, McDonald CF, Hill CJ, et al. The evidence of benefits of exercise training in interstitial lung disease: a randomised controlled trial. Thorax. 2017;72:610\u20139.","journal-title":"Thorax"},{"key":"992_CR83","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s12931-018-0884-y","volume":"19","author":"S Perez-Bogerd","year":"2018","unstructured":"Perez-Bogerd S, Wuyts W, Barbier V, et al. Short and long-term effects of pulmonary rehabilitation in interstitial lung diseases: a randomised controlled trial. Respir Res. 2018;19:182.","journal-title":"Respir Res"},{"key":"992_CR84","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S2213-2600(18)30289-3","volume":"6","author":"D Visca","year":"2018","unstructured":"Visca D, Mori L, Tsipouri V, et al. Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): a prospective, open-label, mixed-method, crossover randomised controlled trial. Lancet Respir Med. 2018;6:759\u201370.","journal-title":"Lancet Respir Med"},{"key":"992_CR85","doi-asserted-by":"crossref","unstructured":"Macaluso C, Furcada JM, Alzaher O, et al. The potential impact of azithromycin in idiopathic pulmonary fibrosis. Eur Respir J. 2019;53(2):1800628.","DOI":"10.1183\/13993003.00628-2018"},{"key":"992_CR86","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1164\/rccm.201611-2201PP","volume":"196","author":"M Vasakova","year":"2017","unstructured":"Vasakova M, Morell F, Walsh S, et al. Hypersensitivity pneumonitis: perspectives in diagnosis and management. Am J Respir Crit Care Med. 2017;196:680\u20139.","journal-title":"Am J Respir Crit Care Med"},{"key":"992_CR87","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s00296-014-3196-7","volume":"35","author":"E Loza","year":"2015","unstructured":"Loza E, Lajas C, Andreu JL, et al. Consensus statement on a framework for the management of comorbidity and extra-articular manifestations in rheumatoid arthritis. Rheumatol Int. 2015;35:445\u201358.","journal-title":"Rheumatol Int"},{"key":"992_CR88","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","volume":"390","author":"CP Denton","year":"2017","unstructured":"Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390:1685\u201399.","journal-title":"Lancet"},{"key":"992_CR89","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12931-018-0769-0","volume":"19","author":"L Schwarzkopf","year":"2018","unstructured":"Schwarzkopf L, Witt S, Waelscher J, et al. Associations between comorbidities, their treatment and survival in patients with interstitial lung diseases\u2014a claims data analysis. Respir Res. 2018;19:73.","journal-title":"Respir Res"},{"key":"992_CR90","first-page":"75","volume":"35","author":"O Distler","year":"2017","unstructured":"Distler O, Brown KK, Distler JHW, et al. Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS). Clin Exp Rheumatol. 2017;35:75\u201381.","journal-title":"Clin Exp Rheumatol"},{"key":"992_CR91","doi-asserted-by":"publisher","first-page":"e000212","DOI":"10.1136\/bmjresp-2017-000212","volume":"4","author":"KR Flaherty","year":"2017","unstructured":"Flaherty KR, Brown KK, Well AU, et al. Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease. BMJ Open Respir Res. 2017;4:e000212.","journal-title":"BMJ Open Respir Res"},{"key":"992_CR92","doi-asserted-by":"publisher","first-page":"e000289","DOI":"10.1136\/bmjresp-2018-000289","volume":"5","author":"TM Maher","year":"2018","unstructured":"Maher TM, Corte TJ, Fischer A, et al. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: design of a double-blind, randomised, placebo-controlled phase II trial. BMJ Open Respir Res. 2018;5:e000289.","journal-title":"BMJ Open Respir Res"},{"key":"992_CR93","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1186\/s13063-017-2016-2","volume":"18","author":"P Saunders","year":"2017","unstructured":"Saunders P, Tsipouri V, Keir GJ, et al. Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial. Trials. 2017;18:275.","journal-title":"Trials"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-00992-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-019-00992-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-00992-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T23:13:46Z","timestamp":1590016426000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-019-00992-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,22]]},"references-count":93,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["992"],"URL":"https:\/\/doi.org\/10.1007\/s12325-019-00992-9","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,22]]},"assertion":[{"value":"10 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}